neopterin
first
isol
larva
bee
worker
bee
royal
jelli
subsequ
human
urin
sakurai
goto
neopterin
pteridin
produc
guanosin
triphosph
via
guanosin
triphosph
cyclohydrolas
gtpch
activ
monocyt
macrophag
dendrit
cell
endotheli
cell
lesser
extent
renal
epitheli
cell
fibroblast
vascular
smooth
muscl
cell
upon
stimul
mainli
interferon
gamma
lesser
extent
interferon
alpha
beta
releas
enhanc
tumor
necrosi
factor
gtpch
mrna
express
synergist
independ
induc
interferon
gamma
pathway
nuclear
transcript
regul
tnf
nfkappab
pathway
see
figur
releas
respons
cytokin
releas
tlymphocyt
natur
killer
cell
make
neopterin
indic
activ
cell
mediat
immun
includ
releas
infect
associ
activ
tlymphocyt
natur
killer
cell
malign
autoimmun
diseas
reject
transplant
organ
atherosclerosi
first
isol
neopterin
detect
pupa
bee
anion
exchang
chromatographi
follow
paper
chromatographi
seventi
ga
chromatographicmassfragmentograph
method
describ
allow
measur
urin
subsequ
detect
quantif
neopterin
succeed
serum
urin
bodi
fluid
use
standard
high
pressur
reversephas
highperform
liquid
chromatographi
fluoresc
detect
later
simpler
radioimmunoassay
recent
enzymelink
immunosorb
assay
develop
suitabl
larg
number
sampl
semiquantit
measur
dipstick
system
use
polyclon
antineopterin
antibodi
valid
may
suitabl
bedsid
test
set
develop
countri
acut
viral
infect
increas
neopterin
level
observ
correl
activ
diseas
first
describ
subsequ
neopterin
elev
note
infect
hepat
virus
epsteinbarr
cytomegalo
measl
mump
varicella
zoster
rubella
influenza
virus
elev
neopterin
level
bodi
fluid
found
end
incub
period
onset
clinic
symptom
highest
neopterin
level
occur
specif
antibodi
viru
becom
detect
two
four
week
onset
increas
neopterin
product
acut
varicella
zoster
viru
infect
peak
neopterin
level
observ
end
appear
rash
measl
viru
infect
one
three
day
appear
rash
immunis
live
virus
exampl
measl
mump
rubella
viru
vaccin
result
signific
increas
neopterin
independ
presenc
symptom
measl
vaccin
neopterin
level
observ
rise
median
day
vaccin
day
appear
antibodi
investig
point
futur
applic
measur
neopterin
correl
success
vaccin
neopterin
investig
marker
evalu
protect
efficaci
vaccin
stimul
cell
mediat
immun
mycobacteri
parasit
viral
diseas
magnitud
elicit
neopterin
level
could
put
relationship
incid
diseas
immunis
popul
immunis
children
serum
neopterin
level
also
found
significantli
elev
symptomat
dengu
viru
infect
level
higher
measl
influenza
viru
diseas
level
correl
durat
fever
sever
diseas
investig
physiolog
function
neopterin
viral
infect
reveal
abl
delay
develop
cytopath
effect
coxsacki
viru
cell
propos
mechan
stimul
induc
nitric
oxid
synthas
express
lead
increas
nitric
oxid
product
mechan
includ
induct
transloc
nuclear
factorkappa
b
nucleu
test
sampl
hiv
infect
individu
found
sampl
rna
antigen
posit
elev
neopterin
level
nmoll
sampl
antigen
neg
elev
neopterin
level
neopterin
level
also
found
significantli
elev
infect
compar
control
studi
investig
marker
immun
activ
use
prognost
marker
hiv
infect
show
increas
neopterin
level
peopl
hiv
infect
compar
patient
without
hiv
infect
neopterin
level
herebi
found
increas
earli
cours
hiv
infect
preceed
declin
clinic
manifest
aid
plasma
neopterin
level
found
correl
plasma
hiv
viral
load
neopterin
level
found
predict
hiv
relat
mortal
retrospect
studi
compar
microglobulin
immunoglobulin
g
adenosin
deaminas
neopterin
level
normal
rang
predictor
clinic
immunolog
deterior
patient
hiv
infect
chang
microglobulin
level
show
greatest
sensit
detect
worsen
neopterin
slightli
less
sensit
follow
immunoglobulin
level
adenosin
deaminas
level
lowest
sensit
land
mark
studi
effect
dual
revers
transcriptas
inhibitor
rt
therapi
highli
activ
antiretrovir
therapi
haart
neopterin
level
patient
hiv
infect
compar
hiv
uninfect
control
hiv
infect
patient
treatment
patient
stop
treatment
rt
inhibitor
treatment
decreas
circul
level
neopterin
mean
treat
versu
mean
ngml
untreat
hiv
patient
p
haart
decreas
neopterin
level
significantli
confirm
result
previou
studi
effect
haart
neopterin
level
neopterin
level
patient
discontinu
haart
becam
similar
untreat
hiv
patient
neopterin
may
particularli
use
surrog
marker
monitor
control
hiv
replic
set
develop
countri
hiv
rna
viral
load
measur
avail
may
cheaper
altern
particularli
semiquantit
dip
stick
test
use
urin
sampl
longitudin
serial
measur
individu
could
overcom
difficulti
interpret
set
chronic
parasit
malaria
bacteri
tuberculosi
infect
may
elev
baselin
neopterin
level
could
allow
monitor
respons
antiretrovir
treatment
absenc
resist
test
provid
mean
monitor
complianc
outpati
set
see
tabl
list
diseas
neopterin
level
use
monitor
treatment
respons
first
studi
investig
role
neopterin
specif
form
viral
hepat
test
urinari
level
patient
hepat
hepat
b
nona
nonb
hepat
viru
infect
author
note
patient
acut
viral
hepat
patient
elev
urinari
neopterin
level
highest
level
found
patient
acut
hepat
patient
activ
hepat
b
elev
neopterin
level
hbsag
carrier
normal
urinari
neopterin
level
author
note
neopterin
level
reflect
hepatocellular
damag
patient
alcohol
hepat
normal
urinari
neopterin
level
order
address
question
whether
neopterin
use
marker
earli
detect
viral
infect
donat
blood
product
seroconvers
one
studi
investig
neopterin
level
antihcvneg
specimen
hcv
rna
hcv
core
antigen
posit
investig
found
elev
neopterin
level
nmoll
specimen
posit
hbv
dna
elev
neopterin
level
patient
thalassemia
major
receiv
multipl
blood
transfus
significantli
patient
histolog
proven
chronic
hepat
anti
hcv
antibodi
posit
elev
blood
neopterin
level
compar
patient
siderosi
liver
alanin
aminotransferas
level
hcv
infect
person
correl
significantli
neopterin
level
serum
neopterin
level
found
use
predictor
respons
treatment
chronic
hcv
infect
pegyl
interferon
combin
ribavirin
neopterin
concentr
evalu
hcv
patient
treat
pegyl
interferon
combin
ribavirin
mean
median
pretreat
neopterin
concentr
lower
patient
sustain
virolog
respons
nonrespond
rate
respons
twofold
higher
among
patient
pretreat
neopterin
level
nmoll
patient
neopterin
level
nmoll
even
control
hcv
genotyp
statu
recent
studi
investig
specif
whether
serum
neopterin
level
discrimin
patient
replic
n
nonrepl
n
hbv
carriag
replic
hbv
carriag
defin
hbv
dna
pgml
hybrid
captur
system
neopterin
level
mean
nmoll
replic
versu
nmoll
nonrepl
hbv
carrier
p
result
reproduc
anoth
studi
found
patient
replic
hbv
infect
n
mean
serum
neopterin
level
nmoll
nonrepl
hbv
n
nmoll
differ
statist
signific
may
due
larg
standard
deviat
small
number
group
recent
investig
found
chronic
hepat
mean
sd
serum
neopterin
level
nmoll
nmoll
patient
liver
cirrhosi
nmoll
control
group
serum
neopterin
level
significantli
higher
patient
chronic
hepat
p
cirrhosi
patient
p
control
subject
cirrhot
patient
significantli
higher
serum
neopterin
level
patient
chronic
hepat
p
posit
correl
serum
neopterin
level
alanin
aminotransferas
level
patient
chronic
hepat
r
p
cirrhot
patient
r
p
posit
correl
detect
serum
neopterin
level
inflammatori
score
patient
chronic
hepat
r
p
cirrhot
patient
r
p
neopterin
investig
marker
distinguish
viral
bacteri
lower
respiratori
tract
infect
investig
found
serum
neopterin
level
elev
nmoll
patient
viral
lrti
median
serum
neopterin
concentr
almost
higher
viral
lrti
group
bacteri
lrti
patient
versu
nmoll
higher
healthi
control
specif
correct
identif
viral
lrti
cutoff
nmoll
serial
monitor
serum
neopterin
level
patient
sever
acut
respiratori
syndrom
sar
associ
viru
reveal
n
investig
patient
elev
neopterin
level
day
durat
pyrexia
sar
patient
correl
posit
neopterin
level
patient
steroid
therapi
significantli
lower
neopterin
level
measur
neopterin
isol
relationship
inflammatori
marker
like
procalcitonin
creactiv
protein
investig
discriminatori
power
viral
bacteri
lower
respiratori
tract
infect
investig
use
crpneopterin
ratio
cn
ratio
discrimin
viral
bacteri
etiolog
respiratori
tract
infect
studi
conduct
hong
kong
sera
obtain
day
hospit
lrti
patient
confirm
bacteri
etiolog
patient
viral
etiolog
examin
sera
healthi
chines
subject
infect
includ
control
area
receiv
oper
characterist
roc
curv
area
curv
auc
distinguish
bacteri
viral
infect
crp
pct
auc
distinguish
viral
bacteri
infect
neopterin
marker
use
combin
auc
roc
cn
ratio
wherea
crp
pct
neopterin
subsequ
report
studi
median
cn
ratio
time
higher
patient
bacteri
aetiolog
viral
aetiolog
versu
mgnmol
p
time
higher
healthi
subject
versu
mgnmol
p
area
receiv
oper
characterist
curv
cn
ratio
cutoff
valu
cn
ratio
rule
inout
bacterialvir
infect
yield
optim
sensit
specif
respect
earli
studi
show
elev
neopterin
level
cerebrospin
fluid
csf
patient
asept
mening
herp
simplex
measl
viru
encephalomyel
csf
level
neopterin
seem
reflect
intrathec
product
microglia
pterin
low
permeabl
across
blood
brain
barrier
serumtocsf
distribut
quotient
recent
establish
normal
csf
neopterin
brainderiv
interindividu
variat
csf
neopterin
healthi
adult
found
depend
serum
neopterin
concentr
variat
coeffici
variat
cvcsf
cvserum
addit
individu
normal
csf
neopterin
concentr
found
invari
variat
albumin
quotient
qalb
csf
neopterin
deriv
leptomening
patient
viral
mening
elev
csf
neopterin
level
compar
healthi
control
normal
serum
level
csf
neopterin
level
correl
herebi
csf
monocyt
cell
count
patient
variou
form
enceph
includ
caus
herp
simplex
viru
varicella
zoster
viru
tick
born
enceph
viru
significantli
elev
csf
neopterin
level
compar
control
higher
level
patient
viral
mening
without
overlap
level
two
condit
hiv
infect
clear
relationship
sever
aidsrel
dementia
csf
neopterin
level
higher
csf
hiv
viral
load
associ
higher
csf
neopterin
level
commenc
combin
antiretrovir
therapi
art
csf
neopterin
decreas
markedli
remain
slightli
normal
level
substanti
number
patient
despit
sever
year
receiv
art
even
patient
system
virolog
failur
exhibit
substanti
reduct
csf
neopterin
concentr
though
virolog
suppress
patient
patient
combin
art
lowest
csf
neopterin
level
found
patient
lowest
csf
viral
load
copiesml
signific
differ
csf
neopterin
concentr
found
treat
proteas
inhibitor
nonnucleosid
revers
transcriptas
base
regimen
combin
nucleosid
analogu
would
support
idea
viral
replic
within
close
csf
least
extent
partli
drive
inflammatori
respons
also
suggest
inflammatori
respons
trigger
may
lead
selfsustain
state
cellular
activ
seen
patient
herp
simplex
viru
enceph
find
studi
consist
report
hiv
rna
level
measur
csf
plasma
significantli
associ
csf
neopterin
trajectori
addit
studi
particip
experienc
virolog
control
limit
standard
detect
result
treatment
csf
neopterin
level
factor
strongli
associ
subsequ
decay
rate
ultim
setpoint
level
basi
vitro
vivo
data
show
macrophag
releas
neopterin
respons
stimul
tlymphocyt
fuch
et
al
investig
urinari
neopterin
level
hplc
patient
cultur
confirm
pulmonari
tuberculosi
compar
normal
control
patient
level
upper
toler
limit
contain
probabl
healthi
control
neopterin
level
higher
age
gender
match
control
everi
extent
pulmonari
diseas
correl
extent
correl
extent
pulmonari
tuberculosi
also
demonstr
serum
level
level
found
bronchioalveolar
lavag
fluid
subsequ
studi
show
higher
level
neopterin
serum
pleural
effus
patient
pulmonari
tuberculosi
compar
control
peripher
blood
mononuclear
cell
pbmnc
tuberculosi
patient
show
significantli
higher
spontan
product
neopterin
stimul
phytohaemagglutinin
purifi
protein
deriv
yield
higher
neopterin
product
pbmnc
patient
tuberculosi
show
product
capac
neopterin
differ
elev
serum
neopterin
level
also
found
hiv
infect
patient
tuberculosi
decreas
significantli
antitubercul
treatment
relaps
tuberculosi
case
character
increas
neopterin
level
studi
compar
neopterin
level
urin
serum
bronchoalveolar
lavag
fluid
found
correl
significantli
patient
tuberculosi
elev
neopterin
patient
tuberculosi
pronounc
urin
serum
bronchoalveolar
lavag
patient
pulmonari
tuberculosi
significantli
higher
urinari
neopterin
level
compar
patient
lung
cancer
pneumonia
twice
concentr
report
adult
pleural
fluid
neopterin
level
investig
abil
differenti
tubercul
malign
pleural
effus
found
significantli
higher
patient
pleural
tuberculosi
perform
characterist
includ
receiveroper
characterist
curv
analysi
inferior
adenosin
deaminas
wait
result
suscept
test
select
effect
antituberculosi
drug
regimen
often
caus
delay
effect
treatment
disastr
especi
children
xray
chang
tend
resolv
slowli
may
get
even
wors
start
therapi
paradox
reaction
due
immunereconstitut
even
otherwis
immunecompet
patient
clinic
statu
reliabl
paramet
reflect
success
failur
drug
regimen
urinari
neopterin
level
declin
twice
weekli
measur
monitor
patient
pulmonari
tuberculosi
treatment
fell
toler
limit
within
week
treatment
patient
measur
serum
neopterin
level
patient
treatment
microbiolog
confirm
pulmonari
tuberculosi
confirm
observ
show
signific
declin
level
near
normal
level
within
month
treatment
context
emerg
multipl
drug
resist
difficulti
monitor
complianc
drug
absorpt
neopterin
need
explor
tool
monitor
success
treatment
mycobacterium
tuberculosi
infect
may
also
help
distinguish
activ
latent
diseas
peopl
hivm
tuberculosi
coinfect
activ
tuberculosi
respond
reduct
plasma
neopterin
antituberculot
treatment
neopterin
level
remain
baselin
level
hiv
neg
tuberculosi
patient
level
higher
patient
lower
count
first
studi
neopterin
level
parasit
infect
includ
measur
urinari
neopterin
hplc
patient
plasmodium
falciparum
vivax
infect
includ
patient
low
grade
parasitemia
patient
elev
urinari
neopterin
level
compar
uninfect
control
level
micromol
neopterinmol
creatinin
level
patient
treat
quinin
sulphat
level
untreat
patient
significantli
differ
subsequ
detail
intervent
studi
provid
data
urinari
neopterin
level
volunt
experiment
infect
plasmodium
falciparum
serial
monitor
reveal
urinari
neopterin
level
elev
peripher
blood
parasit
densiti
increas
cycl
intraerythrocyt
schizogoni
sharp
rise
urinari
neopterin
detect
begin
day
infect
increas
one
day
onset
fever
one
patient
urinari
neopterin
increas
note
without
occurr
fever
neopterin
product
falciparum
malaria
seem
direct
effect
plasmodi
antigen
monocytesmacrophag
vitro
studi
show
monocyt
cell
line
could
stimul
produc
neopterin
lysat
plasmodium
falciparum
parasit
human
erythrocyt
recombin
p
falciparum
protein
cutoff
point
ngml
neopterin
posit
neg
predict
valu
detect
sever
falciparum
malaria
chloroquin
treatment
follow
reduct
urinari
neopterin
level
clinic
diseas
resolv
within
day
treatment
neopterin
level
normal
rapidli
neopterin
level
nonimmun
patient
young
children
higher
semiimmun
individu
csf
csf
neopterin
level
investig
abil
discrimin
differ
stage
cerebr
trypanosoma
brucei
b
gambiens
infect
investig
b
gambiens
patient
origin
angola
chad
democrat
republ
congo
csf
igm
neopterin
best
discrimin
two
stage
diseas
specif
respect
sensit
valid
cohort
patient
test
neopterin
nmoll
correctli
classifi
patient
confirm
high
stage
power
serum
neopterin
also
assess
diseas
marker
human
schistosoma
mansoni
infect
level
found
reflect
extent
hepat
involv
higher
level
found
patient
hepatomegali
treatment
praziquantel
led
normalis
serum
neopterin
level
result
reduct
egg
induc
immunopatholog
detect
new
blood
born
virus
includ
hiv
nona
nonb
hepat
virus
led
investig
new
way
exclud
transmiss
blood
born
virus
transfus
blood
product
govern
tirol
austria
introduc
routin
measur
neopterin
level
donat
blood
cutoff
nmoll
use
led
exclus
donor
total
number
donor
common
caus
elev
level
case
viral
respiratori
tract
infect
donor
elev
neopterin
acut
toxoplasmosi
hiv
infect
nonanon
bhepat
anoth
studi
donat
increas
neopterin
level
posit
cmv
igm
indic
acut
infect
patient
low
neopterin
level
cmv
igm
seroconvers
detect
patient
initi
elev
neopterin
level
second
serum
sampl
indic
neopterin
may
preced
appear
cmv
antibodi
week
studi
austrian
blood
donor
show
neopterin
level
significantli
higher
earli
compar
late
infect
carrier
state
earli
infect
seroconvers
elev
neopterin
level
late
carrier
state
recent
studi
found
use
neopterin
elisa
cmv
dnaposit
sampl
elev
neopterin
level
regard
virus
donor
normal
neopterin
epsteinbarr
viru
igm
gener
almost
threefold
greater
chanc
acut
ebv
infect
donor
increas
neopterin
odd
ratio
confid
interv
regard
parvoviru
infect
donor
found
seroposit
parvoviru
igm
later
studi
group
found
hpv
dna
posit
result
amongst
patient
normal
neopterin
level
investig
associ
neopterin
level
chronic
hepat
c
viru
infect
reveal
significantli
patient
elev
neopterin
level
hcv
antibodi
hcv
pcr
posit
hcv
rna
odd
ratio
p
neopterin
nonspecif
marker
activ
cell
mediat
immun
involv
releas
interferon
gamma
neopterin
may
use
marker
accur
estim
extent
diseas
henc
prognosi
knowledg
potenti
caus
elev
overcom
problem
reduc
specif
patient
known
specif
infecti
diseas
longitudin
serial
measur
individu
could
overcom
difficulti
interpret
set
chronic
parasit
malaria
bacteri
tuberculosi
infect
may
elev
baselin
neopterin
level
could
allow
monitor
respons
antiretrovir
antitubercul
antiparasit
treatment
absenc
resist
test
provid
mean
monitor
complianc
outpati
set
see
tabl
particularli
import
current
context
emerg
multipl
drug
resist
hiv
mycobacterium
tuberculosi
neopterin
high
qualiti
elisa
system
measur
urin
blood
level
commerci
avail
underus
marker
clinic
practic
suitabl
introduct
routin
clinic
laboratori
practic
